These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 2663504)

  • 41. Neuromuscular diseases of the gastrointestinal tract. Specific disorders that often get a nonspecific diagnosis.
    Mathias JR; Clench MH
    Postgrad Med; 1995 Mar; 97(3):95-8, 101-2, 105-8. PubMed ID: 7877932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New pharmacologic therapies in gastrointestinal disease.
    Wallace JL; Ferraz JG
    Gastroenterol Clin North Am; 2010 Sep; 39(3):709-20. PubMed ID: 20951926
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of postoperative gastrointestinal atony.
    Verlinden M; Michiels G; Boghaert A; de Coster M; Dehertog P
    Br J Surg; 1987 Jul; 74(7):614-7. PubMed ID: 3620873
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Erythromycin as a prokinetic agent.
    Kaul A
    J Pediatr Gastroenterol Nutr; 2002 Jan; 34(1):13-5. PubMed ID: 11753157
    [No Abstract]   [Full Text] [Related]  

  • 45. Validated tools for evaluating opioid-induced bowel dysfunction.
    Olesen AE; Drewes AM
    Adv Ther; 2011 Apr; 28(4):279-94. PubMed ID: 21437762
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent advances in the pharmacology of gastrointestinal prokinetics.
    Tonini M
    Pharmacol Res; 1996; 33(4-5):217-26. PubMed ID: 8938012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction.
    Andrews PL; Sanger GJ
    Curr Opin Pharmacol; 2002 Dec; 2(6):650-6. PubMed ID: 12482726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders.
    Peeters TL
    Curr Opin Pharmacol; 2006 Dec; 6(6):553-8. PubMed ID: 17011824
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathophysiology and Treatment of Gastrointestinal Motility Disorders in the Acutely Ill.
    Deane AM; Chapman MJ; Reintam Blaser A; McClave SA; Emmanuel A
    Nutr Clin Pract; 2019 Feb; 34(1):23-36. PubMed ID: 30294835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modulation of gastrointestinal motility beyond metoclopramide and domperidone : Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders.
    Madisch A; Vinson BR; Abdel-Aziz H; Kelber O; Nieber K; Kraft K; Storr M
    Wien Med Wochenschr; 2017 May; 167(7-8):160-168. PubMed ID: 28424994
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [On the possibility of using prokinetics in gastroenterology].
    Sheptulin AA; Vize-Khripunova MA
    Klin Med (Mosk); 2010; 88(5):19-22. PubMed ID: 21089451
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cisapride: a gastrointestinal prokinetic drug.
    Barone JA; Jessen LM; Colaizzi JL; Bierman RH
    Ann Pharmacother; 1994 Apr; 28(4):488-500. PubMed ID: 8038476
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CCK1 antagonists: are they ready for clinical use?
    Peter SA; D'Amato M; Beglinger C
    Dig Dis; 2006; 24(1-2):70-82. PubMed ID: 16699265
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ghrelin signaling in the gut, its physiological properties, and therapeutic potential.
    Avau B; Carbone F; Tack J; Depoortere I
    Neurogastroenterol Motil; 2013 Sep; 25(9):720-32. PubMed ID: 23910374
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical pharmacology forum: motility agents and the gastrointestinal tract.
    McCallum RW
    Am J Med Sci; 1996 Jul; 312(1):19-26. PubMed ID: 8686725
    [No Abstract]   [Full Text] [Related]  

  • 56. Translating 5-HT receptor pharmacology.
    Sanger GJ
    Neurogastroenterol Motil; 2009 Dec; 21(12):1235-8. PubMed ID: 19906028
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The enteric nervous system III: a target for pharmacological treatment.
    Hansen MB
    Pharmacol Toxicol; 2003 Jul; 93(1):1-13. PubMed ID: 12828568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of opioid ligands in the irritable bowel syndrome.
    Corazziari E
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():71A-75A. PubMed ID: 10202212
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
    Camilleri M
    Clin Pharmacol Ther; 2012 Jan; 91(1):44-59. PubMed ID: 22071696
    [No Abstract]   [Full Text] [Related]  

  • 60. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.